Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Open Forum
Time to fully embrace multichannel marketing
Starting with the customer and increasing your content is the way to create engaging marketing campaigns, says a Novartis executive.
Pipeline Monitor
Biosim threat stalks Mabthera
The EMA has accepted for review Sandoz's biosim of Roche's Mabthera while Janssen's Darzalex has won a EC approval for myeloma.
Working Life
GSK's volunteer program is changing lives
Australian GSK staff who participate in the company's international volunteer programs say it changes not only the lives of those they help but also their own.
Approvals Action
New anti-lipid market warms up
The registration of Sanofi's PCSK9 inhibitor Praluent (alirocumab) marks the arrival in Australia of the second among the new class of lipid-lowering drugs.
Special Report
What chances drug patent regime will change this time?
The latest set of recommendations for reform of the pharma IP system are only the latest in a long and unsuccessful history of attempts to change the status quo. Will their fate be similar?